Alzheimer's disease & dementia

Novel PET staging system may help monitor Alzheimer disease

(HealthDay)—A staging system of β-amyloid (Aβ) accumulation may be useful for monitoring patients throughout the course of Alzheimer disease (AD), according to a study published online July 17 in JAMA Neurology to coincide ...

Overweight & Obesity

Should obesity be recognized as a disease?

With obesity now affecting almost a third (29%) of the population in England, and expected to rise to 35% by 2030, should we now recognise it as a disease? Experts debate the issue in The BMJ today.

Medications

Data shows flood of opioids across US, many of them generics

The maker of OxyContin has been cast as the chief villain in the nation's opioid crisis. But newly released government figures suggest Purdue Pharma had plenty of help in flooding the U.S. with billions of pills even as overdose ...

Other

EU greenlights GSK-Pfizer joint venture

The EU on Wednesday approved the merger of the consumer healthcare activities of pharmaceutical giants GlaxoSmithKline and Pfizer that produce over-the-counter medicines.

Medications

History of liver disease does not impact efficacy of edoxaban

(HealthDay)—For patients with atrial fibrillation (AF), the efficacy and safety of edoxaban versus warfarin is not altered with a history of liver disease, according to a study published in the July 16 issue of the Journal ...

Surgery

Operating time for hip, knee replacement overestimated

(HealthDay)—The Medicare Physician Fee Schedule and most recent Relative Value Scale Update Committee recommendations overestimate the operating time for original and revision hip and knee replacements, according to a study ...

Neuroscience

Self-management strategies offer limited benefit in epilepsy

(HealthDay)—Limited evidence suggests that self-management strategies modestly improve some outcomes among persons with epilepsy, according to a review published online July 2 in the Annals of Internal Medicine.

Other

AbbVie makes $63B bid for Botox maker Allergan

Facing competition for the world's top-selling drug, AbbVie is jumping on this year's pharmaceutical merger bandwagon with a $63 billion bid for Botox maker Allergan that's meant to spur future growth.

Oncology & Cancer

High response seen for chemo in seniors with high-risk AML

(HealthDay)—A substantial proportion of older patients with high-risk acute myeloid leukemia (AML) treated with chemotherapy are long-term survivors, according to research published online June 7 in Cancer Medicine.

page 1 from 20